Preventive Dosing for Recurrent Genital Herpes
For adults with recurrent genital herpes requiring suppressive therapy, use acyclovir 400 mg orally twice daily, valacyclovir 500-1000 mg once daily, or famciclovir 250 mg twice daily—all are equally effective at reducing recurrence frequency by ≥75% in patients with frequent recurrences (≥6 episodes per year). 1
Who Should Receive Suppressive Therapy
Suppressive therapy is indicated for patients with:
- Six or more recurrences per year (this is the threshold where benefit clearly outweighs burden) 1
- Significant psychological distress from recurrent episodes
- Desire to reduce transmission risk to sexual partners
The decision should be made after discussing both episodic and suppressive treatment options with all patients who have recurrent genital herpes 1.
Recommended Suppressive Regimens
The following regimens are all effective and FDA-approved 1:
First-line options:
- Acyclovir 400 mg orally twice daily (most cost-effective, longest safety data—up to 6 years)
- Valacyclovir 500 mg orally once daily (convenient dosing)
- Valacyclovir 1000 mg orally once daily (preferred for very frequent recurrences ≥10/year)
- Famciclovir 250 mg orally twice daily
Important caveat: Valacyclovir 500 mg once daily is less effective than other regimens in patients with ≥10 recurrences per year—use 1000 mg once daily or twice-daily dosing instead 1, 2.
Duration and Reassessment
- After 1 year of continuous suppressive therapy, discontinue and reassess the patient's recurrence rate and psychological adjustment 1
- Recurrence frequency naturally decreases over time in many patients, so ongoing suppression may not be necessary 1
- Acyclovir has documented safety for up to 6 years of continuous use; valacyclovir and famciclovir data extend to 1 year in the older guidelines, though more recent evidence supports longer use 1, 3
Key Clinical Considerations
Efficacy: All suppressive regimens reduce recurrence frequency by 70-80% 4, 2. However, they do not eliminate asymptomatic viral shedding completely, so transmission risk remains though it is reduced 1.
Resistance: Clinically significant acyclovir resistance has not emerged among immunocompetent patients on long-term suppressive therapy 1.
Convenience vs. cost: Valacyclovir and famciclovir offer more convenient dosing (once or twice daily) compared to acyclovir, which may improve adherence for prolonged treatment, but they are more expensive 1, 4.
Alternative: Episodic Treatment
For patients who prefer not to take daily medication or have infrequent recurrences (<6 per year), episodic treatment at the first sign of prodrome or lesions is an option 1:
- Acyclovir 400 mg TID for 5 days, OR
- Acyclovir 800 mg BID for 5 days, OR
- Valacyclovir 500 mg BID for 5 days, OR
- Famciclovir 125 mg BID for 5 days
Critical point: Patients must initiate treatment within 1 day of prodrome or lesion onset for episodic therapy to be effective 1.
Common Pitfalls to Avoid
- Don't use valacyclovir 500 mg once daily in patients with ≥10 recurrences per year—it's inadequate 1
- Don't forget to reassess after 1 year of suppressive therapy—many patients can discontinue or reduce frequency 1
- Don't promise complete prevention of transmission—suppressive therapy reduces but does not eliminate asymptomatic shedding 1
- Avoid topical acyclovir—it is substantially less effective than oral therapy 5